How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story

CDK4/6 inhibitors in association with endocrine therapy represent the best therapeutic choice for either endocrine-sensitive or resistant hormone-receptor-positive advanced breast cancer patients. On the contrary, the optimal therapeutic strategy after the failure of CDK4/6 inhibitors-based treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Cogliati, Viola, Capici, Serena, Pepe, Francesca Fulvia, di Mauro, Pierluigi, Riva, Francesca, Cicchiello, Federica, Maggioni, Claudia, Cordani, Nicoletta, Cerrito, Maria Grazia, Cazzaniga, Marina Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954717/
https://www.ncbi.nlm.nih.gov/pubmed/35330128
http://dx.doi.org/10.3390/life12030378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954717/
https://www.ncbi.nlm.nih.gov/pubmed/35330128
http://dx.doi.org/10.3390/life12030378

Ejemplares similares